Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036808 | 0.85 | MGLL (0.33) | MGLLBRD4 | |
| SCHEMBL17776323 | 0.85 | MGLL (0.33) | MGLLBRD4 | |
| SCHEMBL19006080 | 0.85 | MGLL (0.30) | MGLL | |
| SCHEMBL18352374 | 0.85 | MGLL (0.40) | MGLLBRD4ALDH1A1GAAMEN1 | |
| SCHEMBL16315954 | 0.85 | MGLL (0.40) | MGLLBRD4ALDH1A1GAAMEN1 | |
| SCHEMBL2612613 | 0.84 | — | — | |
| SCHEMBL8400082 | 0.82 | BRD4 (0.33) | MGLLBRD4 | |
| SCHEMBL19658174 | 0.78 | MGLL (0.31) | MGLLBRD4 | |
| SCHEMBL18751694 | 0.78 | MGLL (0.31) | MGLLBRD4 | |
| SCHEMBL17776064 | 0.77 | MGLL (0.33) | MGLLBRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137821-A1 | IMMUNOGENIC CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137821-A1 | IMMUNOGENIC CONJUGATES AND USE THEREOF | VAPB, CHMP4B, CD14 | MGLL 2332/4885BRD4 4460/4885ALDH1A1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.